Home  »  Business   »  Wall Street Pummels Cidara Therapeutics Inc. (CDTX...

Wall Street Pummels Cidara Therapeutics Inc. (CDTX) After Recent Earnings Report

Cidara Therapeutics Inc. (NASDAQ:CDTX) went down by -39.28% from its latest closing price compared to the recent 1-year high of $1.60. The company’s stock price has collected -34.73% of loss in the last five trading sessions.

Is It Worth Investing in Cidara Therapeutics Inc. (NASDAQ :CDTX) Right Now?

Plus, the 36-month beta value for CDTX is at 1.38. Opinions of the stock are interesting as 2 analysts out of 3 who provided ratings for Cidara Therapeutics Inc. declared the stock was a “buy,” while 1 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

The average price from analysts is $4.67, which is $4.72 above the current price. CDTX currently public float of 63.36M and currently shorts hold a 0.89% ratio of that float. Today, the average trading volume of CDTX was 434.95K shares.

CDTX’s Market Performance

CDTX stocks went down by -34.73% for the week, with a monthly jump of 62.68% and a quarterly performance of 38.15%, while its annual performance rate touched -13.22%. The volatility ratio for the week stands at 30.55% while the volatility levels for the past 30 days are set at 18.99% for Cidara Therapeutics Inc. The simple moving average for the period of the last 20 days is -12.10% for CDTX stocks with a simple moving average of 18.78% for the last 200 days.

Analysts’ Opinion of CDTX

Many brokerage firms have already submitted their reports for CDTX stocks, with H.C. Wainwright repeating the rating for CDTX by listing it as a “Buy.” The predicted price for CDTX in the upcoming period, according to H.C. Wainwright is $6 based on the research report published on December 03rd of the previous year 2021.

WBB Securities, on the other hand, stated in their research note that they expect to see CDTX reach a price target of $6.25. The rating they have provided for CDTX stocks is “Strong Buy” according to the report published on September 22nd, 2021.

Aegis Capital gave a rating of “Buy” to CDTX, setting the target price at $9 in the report published on March 04th of the previous year.

CDTX Trading at 10.61% from the 50-Day Moving Average

After a stumble in the market that brought CDTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -51.04% of loss for the given period.

Volatility was left at 18.99%, however, over the last 30 days, the volatility rate increased by 30.55%, as shares surge +64.52% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +39.87% upper at present.

During the last 5 trading sessions, CDTX fell by -34.73%, which changed the moving average for the period of 200-days by -13.92% in comparison to the 20-day moving average, which settled at $0.9065. In addition, Cidara Therapeutics Inc. saw 3.57% in overturn over a single year, with a tendency to cut further gains.

Insider Trading

Reports are indicating that there were more than several insider trading activities at CDTX starting from Shah Preetam, who sale 15,642 shares at the price of $0.77 back on Sep 19. After this action, Shah Preetam now owns 150,789 shares of Cidara Therapeutics Inc., valued at $12,035 using the latest closing price.

Sandison Taylor, the Chief Medical Officer of Cidara Therapeutics Inc., sale 18,478 shares at $0.68 during a trade that took place back on Sep 12, which means that Sandison Taylor is holding 291,753 shares at $12,656 based on the most recent closing price.

Stock Fundamentals for CDTX

Current profitability levels for the company are sitting at:

  • -85.24 for the present operating margin
  • +99.62 for the gross margin

The net margin for Cidara Therapeutics Inc. stands at -85.67. Equity return is now at value -502.30, with -58.60 for asset returns.

The liquidity ratio also appears to be rather interesting for investors as it stands at 2.11.